Eps Corp operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eps Corp with three other
companies in this sector in Japan:
Morishita Jintan Co., Ltd.
sales of 9.82 billion Japanese Yen [US$94.73 million]
of which 65%
was Health Care Business),
Shin Nippon Biomedical Laboratories Ltd
(17.84 billion Japanese Yen [US$172.11 million]
of which 66%
was Pre-Clinical Business), and
Takara Bio Inc
(25.97 billion Japanese Yen [US$250.60 million]
of which 91%
was Bio support).
Eps Corp reported sales of ¥45.20 billion (US$436.20 million)
September of 2015.
increase of 8.1%
versus 2014, when the company's sales were ¥41.80 billion.
Sales at Eps Corp have increased during each of the previous five years
(and since 2010, sales have increased a total of 53%).
Sales of Global Research Business saw an increase
that was more than double the company's growth rate: sales were up
38.3% in 2015, from
¥1.97 billion to ¥2.72 billion.
Eps Corp also saw significant increases in sales in
Cso-Related Business (up 14.0% to ¥6.73 billion)
Smo Business (up 12.9% to ¥6.45 billion)
Eps Business (up 23.7% to ¥4.25 billion)
Not all segments of Eps Corp experienced an increase in sales in 2015:
sales of Others fell 36.6% to ¥940.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).